Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

STEATOSIS HAS A PROTECTIVE EFFECT AND IS NOT ASSOCIATED WITH MORE SEVERE DISEASE IN HBEAG POSITIVE CHRONIC HBV WITH RAISED ALANINE AMINOTRANSAMINASE

View through CrossRef
Introduction: The impact of steatosis on hepatitis B e antigen (HBeAg)-positive chronic hepatitis B virus (HBV) infection with raised serum alanine aminotransaminase (ALT) remains unknown. To determi Aim: ne the effect of steatosis in 112 treatment naive HBeAg-positive chronic HBV patients with raised serum ALT. Sixty-one of the 112 patient Methods: s (54.5%) had steatosis on liver biopsy (HBV plus Steatosis Group) while 51 of the 112 patients (45.5%) did not (HBV without Steatosis Group). Signicant chronic hepatitis was dened as having a modied histologic activity index 4-16. Results: Fibrosis stage was similar between the HBV plus Steatosis Group and HBV without Steatosis Group (mean 3.03 vs. 3.00; p=NS). Signicant chronic hepatitis was also similar between the HBV plus Steatosis Group and HBV without Steatosis Group [53/61 (86.9%) vs. 38/51 (74.5%), p=NS]. The HBV plus Steatosis Group had a lower intrahepatic hepatitis B surface antigen (HBsAg) when compared with the HBV without Steatosis Group (mean 0.49 vs. 1.00, respectively; p<0.001). Steatosis correlated negatively with intrahepatic HBsAg (r=-0.43, p<0.001). There was a trend that the HBV plus Steatosis group had a lower median serum HBV DNA level when compared with the HBV without Steatosis Group (6.73 vs. 7.62 Log IU/ml; p=0.07). In HBeAg positive chronic HBV infection wi Conclusion: th raised serum ALT levels, steatosis is not associated with an increased severity of liver disease. Steatosis with a lower intrahepatic HBsAg may offer protective effect against HBV.
Title: STEATOSIS HAS A PROTECTIVE EFFECT AND IS NOT ASSOCIATED WITH MORE SEVERE DISEASE IN HBEAG POSITIVE CHRONIC HBV WITH RAISED ALANINE AMINOTRANSAMINASE
Description:
Introduction: The impact of steatosis on hepatitis B e antigen (HBeAg)-positive chronic hepatitis B virus (HBV) infection with raised serum alanine aminotransaminase (ALT) remains unknown.
To determi Aim: ne the effect of steatosis in 112 treatment naive HBeAg-positive chronic HBV patients with raised serum ALT.
Sixty-one of the 112 patient Methods: s (54.
5%) had steatosis on liver biopsy (HBV plus Steatosis Group) while 51 of the 112 patients (45.
5%) did not (HBV without Steatosis Group).
Signicant chronic hepatitis was dened as having a modied histologic activity index 4-16.
Results: Fibrosis stage was similar between the HBV plus Steatosis Group and HBV without Steatosis Group (mean 3.
03 vs.
3.
00; p=NS).
Signicant chronic hepatitis was also similar between the HBV plus Steatosis Group and HBV without Steatosis Group [53/61 (86.
9%) vs.
38/51 (74.
5%), p=NS].
The HBV plus Steatosis Group had a lower intrahepatic hepatitis B surface antigen (HBsAg) when compared with the HBV without Steatosis Group (mean 0.
49 vs.
1.
00, respectively; p<0.
001).
Steatosis correlated negatively with intrahepatic HBsAg (r=-0.
43, p<0.
001).
There was a trend that the HBV plus Steatosis group had a lower median serum HBV DNA level when compared with the HBV without Steatosis Group (6.
73 vs.
7.
62 Log IU/ml; p=0.
07).
In HBeAg positive chronic HBV infection wi Conclusion: th raised serum ALT levels, steatosis is not associated with an increased severity of liver disease.
Steatosis with a lower intrahepatic HBsAg may offer protective effect against HBV.

Related Results

Modulation of HBV infection and replication by cell-derived factors
Modulation of HBV infection and replication by cell-derived factors
[ACCESS RESTRICTED TO THE UNIVERSITY OF MISSOURI AT REQUEST OF AUTHOR.] Hepatitis B virus (HBV) infection is one of the most serious health problems. HBV infection leads to serious...
A predict model to evaluate the level of HBV-DNA for the patients with Chronic Hepatitis B virus (CHB) in clinic: a cross-sectional study
A predict model to evaluate the level of HBV-DNA for the patients with Chronic Hepatitis B virus (CHB) in clinic: a cross-sectional study
Background: The previous studies showed the correlation between HBsAg and serum HBV DNA levels were weak or missing. And the relationship of HBeAg and HBV DNA levels was lack. Obje...
PMO-162 Pregnant mothers with chronic hepatitis B (HBV): how often is treatment needed?
PMO-162 Pregnant mothers with chronic hepatitis B (HBV): how often is treatment needed?
Introduction HBV is a common cause of chronic liver disease worldwide. Vertical transmission is the commonest mode of infection. Since 20...
Quantitative Analysis and Correlation of HBeAg, HBeAb, and HBV DNA in Chronic Hepatitis B Patients in Swat, Khyber Pakhtunkhwa
Quantitative Analysis and Correlation of HBeAg, HBeAb, and HBV DNA in Chronic Hepatitis B Patients in Swat, Khyber Pakhtunkhwa
Aims: The research aims to determine quantitative values of HBeAg and HBeAb concentrations in chronic hepatitis B patients while assessing their relationship with serum hepatitis B...
Understanding the antiviral effects of RNAi-based therapy on chronic hepatitis B infection
Understanding the antiviral effects of RNAi-based therapy on chronic hepatitis B infection
AbstractReaching hepatitis B surface antigen (HBsAg) loss (called functional cure) with approved treatment with pegylated interferon-α(IFN) and/or nucleos(t)ide analogues (NAs) in ...
Distribution of hepatitis B virus genotypes among patients with chronic infection
Distribution of hepatitis B virus genotypes among patients with chronic infection
Abstract: Hepatitis B virus (HBV) can be classified into at least eight genotypes, A–H. We evaluated the distribution HBV genotypes among patients with chronic infection.Methods: ...

Back to Top